Related Experiment Video
Updated: Apr 8, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
925
Summary
Most acute myeloid leukemias (AMLs) show low argininosuccinate synthetase-1 (ASS1) expression. This makes AML cells reliant on external arginine and vulnerable to its depletion.
Area of Science:
- Oncology
- Biochemistry
Background:
- Argininosuccinate synthetase-1 (ASS1) is crucial for de novo arginine synthesis.
- Arginine is an essential amino acid for cancer cell proliferation.
- Altered ASS1 expression is observed in various cancers.
Purpose of the Study:
- To investigate the role of ASS1 in acute myeloid leukemia (AML).
- To determine the impact of ASS1 deficiency on AML cell metabolism and survival.
- To evaluate the therapeutic potential of arginine deprivation in AML.
Main Methods:
- Analysis of ASS1 expression in AML cell lines and primary patient samples.
- Assessment of arginine dependency in ASS1-deficient AML cells.
- Evaluation of cell viability and apoptosis upon arginine deprivation.
Main Results:
- The majority of AML cases exhibit significantly low ASS1 expression.
- AML cell lines and primary AML blasts with low ASS1 are auxotrophic for arginine.
- Arginine deprivation effectively inhibits proliferation and induces cell death in these AML models.
Conclusions:
- Low ASS1 expression is a common feature of AML, creating a metabolic vulnerability.
- Targeting arginine metabolism through deprivation represents a promising therapeutic strategy for AML.
- ASS1 status can potentially stratify AML patients for arginine-targeted therapies.
